Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations.

Our aim was to evaluate correlation between clinicopathological features (clinical T and clinical N stages; histological type; nuclear grade; hormone-receptor and HER2 status, proliferation activity and tumor subtypes) of breast cancer and kinetic parameters measured by staging dynamic FDG-PET/CT examinations. Following ethical approval and patients' informed consent we included 34 patients with 35 primary breast cancers in our prospective study. We performed dynamic PET imaging, and assessed plasma activity noninvasively.

Comparison of different motion correction techniques for dynamic FDG-PET/CT studies in breast cancer patients.

Background: Our aim was to evaluate interchangeability of different motion correction methods in the assessment of dynamic FDG-PET/CT studies in breast cancer patients as well as to assess the interrater reliability of these methods.

Methods: In our prospective study we included patients with malignant breast tumours. Dynamic PET acquisition lasted for 60 minutes after tracer (FDG) injection.

Primary systemic therapy for breast cancer: Does the patient's involvement in decision-making create a new future?

Objective: Primary systemic therapy (PST) followed by surgery is the standard initial treatment for locally advanced breast cancer (LABC). However, some patients are averse to mastectomy or breast-conserving surgery and do not consent to these procedures. The reasons for this controversial decision, the factors influencing the decision-making and optimal solutions for decision aiding need to be investigated.